Sign in
WithdrawnPhase 2

Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
6 Sept 2022
Ended
1 Aug 2024
Type of study
Interventional
Treatments tested
  • Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
Record updated
6 August 2024
Why it stopped
Insufficient enrollment; departure of primary investigator from institution

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age 18-70 years
  • Able to provide informed consent
  • Willing and able to travel to the University of Pennsylvania for routine post-transplant study visits
  • Pre-menopausal women must agree to use birth control in accordance with the Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant
  • Both men and women must agree to use at least one barrier method of birth control or remain abstinent following transplant due to risk of HBV transmission
  • Appropriate HBV vaccine pre-transplant response, defined as HBV sAb ≥12.00 mIU/mL

Who cannot take part

  • Transplant candidate characteristics:; Age >70 years; Any chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD)) associated with persistently elevated liver enzymes; Significant fibrosis (≥F2 on Fibroscan or Fib4 ≥1.67 (for patients unable to complete Fibroscan and without liver disease risk factors)); Inadequate insurance coverage of entecavir, tenofovir disoproxil, or tenofovir alafenamide; Retransplant candidate; Current use of extracorporeal membrane oxygenation (ECMO) or mechanical ventilation as a bridge to lung transplantation; HIV infection; Chronic kidney disease with estimated glomerular filtrate rate less than 50 ml/min/1.73 m2; Small bowel dysmotility or plan for prolonged medications and/or nutrition via tube route in the post-transplant period; Significant human leukocyte antibody (HLA) sensitization (Calculated Panel Reactive Antibody (CPRA) ≥60%); Planned or high likelihood of anti-thymocyte globulin induction immunosuppression or rituximab treatment; Known hypercoagulable states including positive antiphospholipid antibodies with prior venous or arterial thromboembolic events or Factor V Leiden or Prothrombin mutations with or without prior venous or arterial thromboembolic events; History of hypersensitivity or anaphylactic reaction to immune globulin or similar products; Receiving or anticipated to receive drugs with significant entecavir or tenofovir interactions including phenytoin/fosphenytoin, oxcarbazepine, phenobarbital, primidone, rifabutin, and rifampin
  • Donor characteristics:; Donation after circulatory death donor; Hepatitis C Virus (HCV) NAT+; PaO2/FiO2 <300 on FiO2 = 100% and PEEP=5; Age >55 years; Smoking history >20 pack years

Where in United States

  • Hospital of University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

The objective of this study is to determine the safety and efficacy of transplanting lungs from hepatitis B virus (HBV) nucleic acid test positive (NAT+) donors into HBV vaccinated HBV surface antibody positive (sAb+) lung transplant candidates, who will then be treated with Hepatitis B Immune Globulin (HBIG) and entecavir, tenofovir disoproxil, or tenofovir alafenamide.

The group in the trial

  • Recipient of Hepatitis B NAT+ DonorOther group

    All subjects will then be treated with Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide (choice of specific drug to be based on long-term cost, clinical response, and renal function)

    Treatment: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates
Record updated
6 August 2024